Author

Veerendra Kumar Panuganti

Institution: Shilpa (India)

Observed institution: Shilpa (India)

ORCID: 0009-0004-2623-5032

Observed ORCID: 0009-0004-2623-5032

OpenAlex ID: A5114517364

Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients

2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · World Journal of Hepatology · 6

A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia

2025 · Veerendra Kumar Panuganti, Pavan Kumar Madala, et al. · Cureus · 4

Phase I Study Evaluating Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Recombinant Human Serum Albumin (rHSA) in Healthy Adults

2026 · Veerendra Kumar Panuganti, Mamatha Reddy Dundigalla, et al. · Drug Design Development and Therapy · 2

Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study

2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · Advances in Pharmacological and Pharmaceutical Sciences · 1

A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial

2025 · Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, et al. · Cancer Chemotherapy and Pharmacology

Preclinical and Clinical Development of a Novel Ondansetron Extended-Release Injectable Suspension: Evaluation of Safety, Efficacy and Pharmacokinetics in Moderately and Highly Emetogenic Chemotherapy

2024 · Veerendra Kumar Panuganti · Cancer therapy & Oncology International Journal

Works count: 6

Citation count: 13

H-index: 2

I10-index: